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Abstract
Background: MicroRNAs are involved in key cellular processes regulating, and their misregulation is linked to cancer. The miR-302-367
cluster is exclusively expressed in embryonic stem and carcinoma cells. This cluster also promotes cell reprogramming and stemness
process. In contrast, miR-145 is mostly regarded as a tumor suppressor, where it regulates cellular functions such as cell division, differ­
entiation, and apoptosis. By suppressing the main pluripotency factors (OCT4, SOX2, MYC and KLF4), miR-145 silences the self-renewal
program in ESCs. Therefore, the main aim of this study is to find a potential link between the expression level of hsa-miR-302b and hsa­
miR-145 with tumor vs. non-tumor as well as high-grade vs. low-grade states of the esophageal tissue samples.
Methods: A total number of 40 formalin-fixed, paraffin-embedded (FFPE) samples of esophageal squamous-cell carcinoma (ESCC) were
obtained, and the tumor and marginal non-tumor areas delineated and punched off by an expert pathologist. Total RNA was extracted with
Trizol, and cDNA synthesized using the miRCURY LNAM Universal RT microRNA PCR Kit. Real-time reverse transcription polymerase
chain reaction (RT-PCR) assays were performed using specific LNA-primers and SYBR Green master mix.
Results: The expression level of miR-302b failed to show any significant difference, neither between tumor and their non-tumor coun­
terparts, nor among tumors with different grades of malignancies (P > 0.05). In contrast, miR-145 was significantly down regulated in all
grades of tumor samples (P < 0.001). However, its expression level could not discriminate between different grades of malignancy (P >
0.05). Conclusion: Our data revealed a significant down-regulation of miR-145 in ESCC tissue samples. Based on our ROC curve analysis
data (AUC = 0.74, P < 0.001) miR-145 could be regarded as a potential tumor marker for diagnosis of esophageal cancer.
Keywords: Esophageal cancer, FFPE, hsa-miR-302b, hsa-miR-145, molecular marker
-
Introduction
E sophageal cancer (EC) is the eighth most common cancerand the sixth leading cause of cancer-related deathworld­
wide.1–3 EC frequency is higher in men and its occurrence
increases with age, with the highest incidence rate between the
ages of 50 – 70 years, where the mortality rate is about 90% of all
cases.1,2,4 Several epidemiological studies indicated that hot drinks,
alcohol, tobacco and low consumption of fresh fruits and vegeta­
bles are the main risk factors for EC.1,2,5–7 There are two main
forms of EC, each with distinct etiologic and pathologic charac­
teristics. Esophageal squamous cell carcinoma (ESCC) is the
most frequent subtype of EC, whiles the other subtype, adenocar­
cinoma, is less common.1 Geographical distribution of EC is vari­
able. Golestan Province, located in the south-east of the Caspian
Sea in northern Iran, has one of the highest incidence rates of EC
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–
in the world.8 Despite advances in medical and surgical tech­
niques, the EC prognosis remains poor and long-term survival is
in the range of 18% – 25%.9 
MicroRNAs (miRNAs) are a growing class of short (18 – 22
mer) non-coding RNAs which primarily act by complementary
binding to the 3’ UTR of their mRNA targets, therefore blocking
their translation. By post-translational modulation of their targets,
miRNAs play critical regulatory roles in cell growth, prolifera­
tion, differentiation, cell death, and etc. Accumulating evidences
suggest that altered expression of miRNAs results in the initiation
and/or progression of a variety of tumors, where they function
either as oncogenes or tumor suppressors. Due to their high sta­
bility in clinical samples and tissue-specific expression profiles,
miRNAs have been considered as potential biomarkers in cancer
diagnosis and classification.10–12 
Members of the miR-302 cluster (miR-302a, miR-302b, miR­
302c, miR-302d, and miR-367) are the most existing miRNAs in
human embryonic stem cells (hESCs), transcribed from a ~700­
bp region on chromosome 4, and forms a polycistronic transcript.
Its expression is claimed to be restricted to ES and embryonic car­
cinoma (EC) cells, where they are quickly down-regulated upon
differentiation. This cluster is one of the main stemness regulators,
where its ectopic expression is enough to transform cancer cells
to stem cells.13 Interestingly, the ESC-specific transcription factors
including OCT4, SOX2, Nanog and Rex-1 have binding sites on
the miR-302 promoter and hence regulating its expression.13–14 

































































MiR-145 is another important microRNA widely regarded as
a tumor suppressor, where its expression is down-regulated in
PDQ\ FDQFHUV7KLV VSHFL¿F SDWWHUQ RI H[SUHVVLRQ KLJKOLJKWV LWV 
importance as a molecular marker for diagnosis and therapy of
cancers.15–17 MiR-145 is transcribed from a 4.09kb region on chro­
mosome 5 (5q32-33), which is one of the known chromosomal
fragile sites. This can partly explain miR-145 down-regulation
in many cancers. MiR-145 silences the self-renewal program in
ESCs and facilitates their differentiation.18,19 
:KLOHWKH (6VSHFL¿F WUDQVFULSWLRQ IDFWRUV 2&7 62; 
Nanog and Rex-1) bind to miR-302 promoter and induce its ex­
pression in pluripotent cells, the same factors suppress the expres­
sion of miR-145 and induce cell differentiation.20,21According to
previous studies, the expressions of some embryonic miRNAs
are re-expressed in cancers. In this study, we aimed to evaluate
the expression of miR302b and miR-145 in tumor and non-tumor
samples of EC.
Materials and Methods 
Clinical ESCC specimens 
We performed a matched case-control study in which 40 ran­
GRPO\VHOHFWHGIRUPDOLQ¿[HGSDUDI¿QHPEHGGHG))3(WLVVXH 
samples of patients with esophageal SCC and their adjacent non-
tumor tissue samples were obtained from Namazi hospital (Shiraz
University of Medical Sciences, Shiraz/Iran). For each patient, the
clinico-pathological information including gender, age, as well as
thegrade and stage of tumorswere gathered. The experimental
procedures were approved by the ethics committees of Namazi
hospital and Tarbiat Modares University. Representative sections
of FFPE samples were stained with hematoxylin and eosin (H&E)
dyes, and tumor/non-tumor are as delineated by an expert pathol­
ogist (Dr. Mohammad Vasei). 
RNA isolation 
From FFPE blocks of each patient, the tumor and apparently
normal areas were carefully punched off and cut into thin sec­
WLRQV6HFWLRQVZHUHWKHQGHSDUDI¿QL]HGE\[\OHQHWUHDWHGZLWK 
μg/ml of proteinase K (Fermentas, Lithuania) in PK buffer (1mM
EDTA, 1 mM NaCl, 5 mM Tris-HCl, PH 7.4) and incubated at
54oC for 3 hours. Using Trizol reagent (Invitrogen, USA), total
51$ZDVH[WUDFWHGDQGGLVVROYHGLQWRȝORI51DVHIUHH 
water, according to the manufacturer’s instructions.The concen­
trationand purity of RNA were determined by spectrophotometer.
RNase-free DNase (Fermentas, Lithuania) treatment of total RNA
was performed to eliminate any potential contamination with ge­
nomic DNA. 
Real-time RT-PCR assay 
The optimal concentration of total RNA for cDNA synthesis
was determined empirically in the maximum range of RNA con­
centrations suggested by the manufacturer (200ng of total RNA).
Synthesis of cDNA was performed using the mercury LNA™
8QLYHUVDO 57 PLFUR51$ 3&5 .LW ([LTRQ 'HQPDUN %ULHÀ\ 
the tubes were incubated for 60 minutes at 42°C, followed by
heat-inactivation of the reverse transcriptase (RT) enzyme for 5
minutes at 95°C. Real-time RT-PCR was performed using miR­
302b and miR-145 LNA™ primers (Exiqon, Denmark), as well
as SYBR Green master mix (Exiqon, Denmark). 5S rRNA gene
was also used as a housekeeping internal control. PCR reactions
were conducted at 95°C for 10 minutes, followed by 40 cycles
of 95°C for 10 seconds, and 60°C for 1 minute in an ABI 7500
real-time quantitative PCR system (Applied Biosystems, USA).
Human embryonic carcinoma cell line NTERA2 (NT2; kindly
SURYLGHGE\'U3HWHU$QGUHZVDW6KHI¿HOG8QLYHUVLW\ZDVHP­
SOR\HGWRFKHFNWKHVSHFL¿FLW\RIWDUJHWSULPHUVWRDPSOLI\KVD 
miR-302b and hsa-miR-145. Human embryonic carcinoma cell
line NTERA2 was also considered as a positive control.To deter­
PLQHWKHUHDFWLRQHI¿FLHQFLHVIRUHDFKSULPHUSDLU/LQ5HJ3&5 
(12.x) software program (AMC, Amsterdam, http://LinRegPCR. 
nl) was applied, and real-time PCR data were adjusted based on
WKHH[DFW3&5HI¿FLHQF\)RUFDOFXODWLRQRIPL51$VH[SUHVVLRQ 
fold change, the expression level in each sample was normalized
to that of 5S rRNA. Then, miRNAs expression in tumor samples
was adjusted to their matched non-tumor samples (2Aǻǻ&7). For
comparing the expression of miRNAs in tumor and non-tumor
groups, the expression level of each sample was calibrated to that
of the least expressed sample. Furthermore, for each sample a no-
RT control was included to detect any potential genomic DNA
contamination. 
Statistical analysis 
According to the Kolmogorov–Smirnov normality test (KS­
test), statistical differences between well, moderately and poorly
differentiated tumors and their matched non-tumor esophageal
samples were determined either by paired t-test or Wilcoxon
non-parametric test. All tests were performed as two-tailed. P <
ZDVFRQVLGHUHGVWDWLVWLFDOO\VLJQL¿FDQW&RUUHODWLRQVEHWZHHQ 
miRNA expressions were estimated using Spearman correlation
FRHI¿FLHQW5HFHLYHURSHUDWLQJFKDUDFWHULVWLF52&FXUYHDQDO­
ysis was employed to determine whether the expressions of the
DIRUHPHQWLRQHG PL51$V KDYH WKH VHQVLWLYLW\ DQG VSHFL¿FLW\ WR 
discriminate between tumor and non-tumor samples, as well as
between early and advanced stages of tumors. GenEX software
(MultiD Analyses AB, Goteborg, Sweden), and Statistical Pro­
gram for Social Sciences (SPSS) software version 17 (SPSS Inc.,
Chicago, IL, USA) were utilized for statistical analysis of real-
time PCR data. 
Results 
2SWLPL]LQJPL51$VDPSOL¿FDWLRQ 
FFPE samples of 40 patients with ESCC were used in this study.
The pathologic subtypes of tumors were: 9 poorly, 6 moderately
and 25 well differentiated. Using spectrophotometer, the result of
quality control determined acceptable ratios for purity and con­
centration of RNA extractedfrom FFPE samples.
The melt curve analysis of PCR products demonstrated a pre­
dicted single melt curve pick, and hence the authenticity of the
3&5SURGXFWV)LJXUH7KHUHZHUHQRDPSOL¿FDWLRQSURGXFWLQ 
the negative and “no RT” controls. Using real-time RT-PCR, the
PHDQ&7VIRUPL5EDQGPL5DPSOL¿FDWLRQLQDOOVDPSOHV 
(both tumor and non-tumor) were determined as 34.4 ± 1.5 and
22.5 ± 3.2, respectively.We initially employed both U6snRNA
and 5S rRNA as internal controls. However, due to its high Ct
values and wide variation of its expression level, the U6snRNA
TXDQWL¿FDWLRQZDVVWRSSHGLQODWHUH[SHULPHQWV 
Differential expression of miR-302b and miR-145 in esophageal 
tumors and their matched non-tumor tissues 





















The relative expression of miR-302b and miR-145 in 40 paired
of tumor/non-tumor ESCC surgical specimens was determined
E\UHDOWLPH3&5$VLJQL¿FDQWGRZQUHJXODWLRQRIPL5LQ 
tumor samples was detected, compared to their non-tumor coun­
terparts from the same patients (P < 0.001, ). Further analysis
of miR-145 gene expression in tumors with different grades of
PDOLJQDQFLHVUHYHDOHGLWVVLJQL¿FDQWGRZQUHJXODWLRQLQGLIIHUHQW 
JUDGHVRIPDOLJQDQF\SRRUO\3 PRGHUDWHO\S  
DQG ZHOO S   GLIIHUHQWLDWHG VDPSOHV FRPSDUHG WR WKHLU 
non-tumor counterparts. In contrast to miR-145, we could not
GHWHFWDQ\VLJQL¿FDQWGLIIHUHQFHRIPL5EH[SUHVVLRQQHLWKHU 
between tumor vs. non-tumor states nor in different grades of ma­
lignancies (Figure3). 
$FFRUGLQJ WR 6SHDUPDQ FRUUHODWLRQFRHI¿FLHQW QR VLJQL¿FDQW 
and considerable correlation was observed between the expres­
sion levels of miR-302b and miR-145(data not shown). 
















Figure 3. $FRPSDUDVLRQRIPL5EH[SUHVVLRQLQZHOO:'PRGHUDWHO\0'DQG 
poorly (P.D.) differentiated of esophageal tumor samples vs. their matched non-tumor
samples. The red and blue boxes represent tumor and non-tumor samples, respectivily.
,QHDFKVDPSOHWKHH[SUHVVLRQOHYHORIPL5EJHQHLVQRUPDOL]HGWRWKDWRILQWHUQDO 
FRQWURO6U51$DQGWKHQFDOLEUDWHGWRWKDWRIWKHOHDVWH[SUHVVHGVDPSOH)LQDOO\ 





302b gene expression level in tumors vs. their matched non-tumor samples. 
Figure 4.5HFHLYHURSHUDWLQJFKDUDFWHULVWLF52& FXUYH 
DQDO\VLV GHWHUPLQHGD JRRGVHQVLWLYLW\ DQG VSHFL¿FLW\ IRU 
PL5 H[SUHVVLRQ OHYHORQ GLVFULPLQDWLQJ WXPRU IURP 
non-tumor states of the samples. The calculated area un-
GHUWKHFXUYH$8& GHPRQVWUDWHGWKHVXWDELOLW\RI 
PL5WRFRUUHFWO\FODVVLI\WXPRUDQGQRQWXPRUJURXSV 





Association of miR-145 expression with patients’ clinico-pathological 
characteristics: 
Using ROC analysis, the suitability of miR-302b andmiR-145
expression levelswas evaluated to discriminate between tumor
and non-tumor states of the samples. According to ROC curve
analysis, miR-145 seems to be a good candidate for accurate dis­
FULPLQDWLRQRIWXPRUIURPQRQWXPRUVDPSOHV$8& 3 
0.001; Figure 4). As expected, miR-302b was not able to distin­
JXLVK WXPRU IURPQRQWXPRUVDPSOHV $8& 3  
Both miRNAs failed to accurately detect early from advanced
WXPRUVWDJHVS!,QDJUHHPHQWZLWKWKH52&GDWDWKHUH 
ZDVQRVLJQL¿FDQWGLIIHUHQFHEHWZHHQIROGFKDQJHVRIPL51$V¶ 
expression in well, moderately and poorly differentiated grades of
malignancies (Figure 5). 
Discussion 
Accumulating reports have indicated the involvement of mi­
croRNAs in the initiation and/or progression of various types of
tumors. Moreover, it is already showing that the miRNAs expres­
VLRQLVFHOODQGWLVVXHVSHFL¿F22 The cluster of miR-302, which
is the most abundantly expressed miRNA in undifferentiated
(6&VLVDJRRGH[DPSOHRIFHOOVSHFL¿FH[SUHVVLRQ$FFRUGLQJO\ 
miR-302 expression is sharply turned off upon the induction of

























































differentiation.137RGDWH WKHUH DUHVHYHUDO FRQÀLFWLQJ UHSRUWV RQ Authors Contribution 
the role of the miR-302in tumorigenesis. A coordinate over-ex­
pression of all members of the cluster has been just reported for 7KH¿UVWWZRDXWKRUVDUHHTXDOO\FRQWULEXWHGWRWKLVZRUN 
PDOLJQDQWJHUPFHOOWXPRUV*&7GHPRQVWUDWLQJWKHVSHFL¿FLW\ 
of these markers for GCT.23,24 In contrary, some other investiga- References
tors have proposed a tumor suppressor activity for miR-302.25,28
In our study, the detection of miR-302b in ESCC samples did not 1. 
RFFXUDWDUHOLDEOHOHYHORIH[SUHVVLRQ&7 0RUHRYHU 
ZHFRXOGQ¶W¿QGDVLJQL¿FDQWH[SUHVVLRQDOWHUDWLRQRIPL5E 2. 
between tumor vs. non-tumor samples, and also among differ­
ent grades of malignancies. It can be concluded that the expres- 3. 
sion of miR-302b is probably restricted to a rare subpopulation
of cancer stem cells, which exists in almost all cancers includ­ 4. 
ing ESCC.29,30 Accordingly, the expression of the miR-302 is al­
ready reported in a rare stem cell-like subpopulation of glioma
cell line.31Nevertheless, ROC analysis on miR-302b expression
data suggest its unreliable ability to discriminate tumor from non- 5. 
tumor and also early from advanced tumor stages. 
In contrast to miR-302b, the expression level of miR-145 was
much higher in our samples and was detectableat reliable CT val- 6. 
ues (22.5 ± 3.2).The miR-145 is widely regarded as a tumor sup­
pressor and its down-regulation was already reported for many 7. 
cancers, including: breast,32 colon,33 prostate,34 B- cell,35 gastric36 
and bladder.37 In accordance with the previous literature, our data 8.UHYHDOHGDYHU\VLJQL¿FDQWGRZQUHJXODWLRQRIPL5LQWXPRU 
VDPSOHVFRPSDUHGWRWKHLUQRQWXPRUFRXQWHUSDUWV7KLV¿QGLQJLV 
in agreement with the inhibitory role of miR-145 in an undifferen­
tiated state of pluripotent and induced pluripotent stem (ips) cells. 9. 
MiR-145 regulates OCT4, SOX2, and KLF4 and represses pluri­
potency in human embryonic stem cells.18,21 In accordance with
our previous study on miR-145 expression in gastric cancer,38 a 10. 
prominent down-regulation of miR-145 in early stages of esopha­ 11. 
geal tumorigenesis may point to its critical role in the prevention
of tumor initiation. 3UR¿OLQJDOWHUHGH[SUHVVLRQRIPLFUR51$VLQ 
ESCC, Wu and his colleagues reported a deregulation of miR-143 12. 
and miR-145 in tumor samples.39 2XU¿QGLQJDUHFRQVLVWHQWZLWK 13. 
those of other studies,39,40 and suggest that a tumor suppressor ac­
tivity for miR-145 in ESCC. 
Furthermore, the data of ROC curve analysis demonstrated an
14.$8&RIIRUPL57KHKLJKYDOXHRI$8&UHÀHFWVDJRRG 
VSHFL¿FLW\DQGVHQVLWLYLW\IRUDSRWHQWLDOGLDJQRVWLFPDUNHURIHVRSK­
ageal cancer. However, ROC curve analysis failed to discriminate 15. 
HDUO\IURPDGYDQFHGVWDJHVRIWXPRUV7KHODWWHU¿QGLQJPLJKWEH 
due to the low number of samples in late stages. It also indicates
that miR-145 down-regulation occurred at an early stage of ESCC. 16. 
In our previous study on the same samples, we found that miR-21
is overexpressed in ESCCs, compared to their adjacent non-tumor 17.
tissues (P < 0.001).41 MiR-21 is an oncomir and its frequent up­
regulationis already reported in different cancers, including ESCCs.
Moreover, the serum concentration of miR-21 in ESCC patients 18. 
ZDVVLJQL¿FDQWO\KLJKHUWKDQWKDWLQKHDOWK\FRQWUROVLQGLFDWLQJWKDW 
miR-21 has a potential to be used as a biomarker for early detection
of ESCC.42 Up-regulation of miR-21, an oncomiR, and down-reg- 19. 
ulation of miR-145, a tumor suppressor miRNA, in early stages of
esophageal tumorigenesis points to their critical roles in promoting 20. 
and prevention of tumor initiation, respectively. 
In conclusion, consideringthe high stability and ease of miR-145 21. 
detection in FFPE samples, evaluation of miR-145 expression in
WXPRUWLVVXHVVHUXPRURWKHUERG\ÀXLGVRISDWLHQWVLVDUHOLDEOH 22. 
biomarker for diagnosis of ESCC. 
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